The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 06, 2021
Filed:
Nov. 14, 2017
Applicant:
Novartis Ag, Basel, CH;
Inventors:
Stephane Ferretti, Huningue, FR;
Nelson Guerreiro, Basel, CH;
Sebastien Jeay, Niffer, FR;
Astrid Jullion, Sierentz, FR;
Christophe Meille, Sierentz, FR;
Jens Wuerthner, Steinen, DE;
Assignee:
Novartis AG, Basel, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/497 (2006.01); A61K 31/505 (2006.01); A61K 31/506 (2006.01); A61P 7/00 (2006.01); A61P 35/02 (2006.01); A61K 45/06 (2006.01); A61K 31/404 (2006.01); A61K 31/4418 (2006.01); A61K 31/4439 (2006.01); A61P 35/00 (2006.01); A61K 31/47 (2006.01); A61K 31/401 (2006.01); A61K 31/4152 (2006.01); A61K 31/496 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 31/404 (2013.01); A61K 31/4418 (2013.01); A61K 31/4439 (2013.01); A61K 31/47 (2013.01); A61K 45/06 (2013.01); A61P 7/00 (2018.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); A61K 31/401 (2013.01); A61K 31/4152 (2013.01); A61K 31/496 (2013.01);
Abstract
The present invention relates to HDM2-p53 interaction inhibitors for use in the treatment of cancer, wherein the drug is administered by a high dose intermittent dosing regimen. The present invention relates in particular to the HDM2-p53 interaction inhibitor HDM20I and the dosing regimen di, d8 of a 4 week cycle.